ストックスクリーナーアプリを入手
1.03
6.19%
0.06
アフターアワーズ：
1.00
-0.03
-2.91%
Creative Medical Technology Holdings Inc (CELZ) 最新ニュース
Form 4 Creative Medical Technology Holdings Inc For: 25 September - Investing.com India
Creative Medical Technology Expands Control of BioDefense Subsidiary - TipRanks
Form 4 Creative Medical Technology Holdings Inc For: 25 September By Investing.com - Investing.com Nigeria
[Form 4] CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Insider Trading Activity - Stock Titan
Creative Medical Technology Takes 80% Control of BioDefense in Cash-and-Stock Purchase - TradingView
These Three Stocks Fell More Than 10% Today To Hit 52-Week Lows -- What's Driving The Investor Skepticism? - Stocktwits
Creative Medical Technology Holdings Stock Price Forecast. Should You Buy CELZ? - StockInvest.us
Creative Medical Technology Holdings Expands Ultrasome Intellectual Property Portfolio with New U.S. Provisional Patent Filing - marketscreener.com
Creative Medical files patent application for Ultrasome platform - Investing.com
Creative Medical files patent application for Ultrasome platform By Investing.com - Investing.com UK
About 93% improved in a knee study. Creative Medical files a patent application. - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Creative Medical Technology Holdings Inc. (CELZ) Key Financial Ratios – Valuation, Profitability & More - Value Research
EPS Creative Health Tech’s Controlling Shareholder to Sell 22% Stake While Retaining Control - TipRanks
Creative Medical Technology Holdings Inc. (CELZ) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Bears are Losing Control Over Healthcare Realty Trust (HR), Here's Why It's a 'Buy' Now - Yahoo Finance
Creative Medical Technology Increases Authorized Shares to 100 Million - minichart.com.sg
Creative Medical Expands Authorized Shares and Warrant Exercise - TipRanks
Creative Medical Technology Holdings Inc. (CELZ) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
CELZ Holds Steady at $1.14 as Creative Medical Technology ConsolidatesDaily Profile - dars.gov.et
Creative Medical Technology Holdings Inc. (CELZ) Peer Comparison – Compare with Others - Value Research
Creative Medical completes Olastrocel trial enrollment as it sets sights on FDA Phase 3 path - Indian Pharma Post
Rest-Of-Europe Exosome Research Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
CELZ Looks 171.4% Overvalued on GF Value™ - GuruFocus
CELZ Looks 142.9% Overvalued on GF Value™ - GuruFocus
Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning - The Manila Times
Creative Medical completes enrollment in chronic back pain trial - Investing.com
Creative Medical Technology Holdings Completes Enrollment And Treatment In FDA-Cleared ADAPT Clinical Trial Evaluating CELZ-201 / Olastrocel - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Creative (CELZ) EPS and Revenue Review: The EPS Result Is Below Expectation on the Day; Market Follow-Through: The Share Price Sheds 1.82% on the DayGuidance Accuracy Score - vinanet.vn
CELZ Q2 2026 Earnings: Wider Loss of -$0.41 per Share Misses Estimates; Stock Falls 1.6%EPS Consistency Score - vinanet.vn
CELZ Q2 2026 Earnings: EPS Miss of -$0.41 Reflects Pre-Revenue Pipeline InvestmentCFO Commentary Report - vinanet.vn
Why Avalon Holdings Shares Are Trading Higher By More Than 10%; Here Are 20 Stocks Moving Premarket - Sahm
CELZ Q2 2026 Earnings: EPS Misses by 3.07% as Pre-Revenue Losses Persist; Stock Climbs 8.75%Capex Guidance - dars.gov.et
CELZ Jumps As New Diabetes Patent Fuels Volatile Rally - StocksToTrade
Creative Medical Technology | DEF 14A: Definitive information statements - Moomoo
Creative Medical net loss widens 22.5% to $1.51 million in Q2 2026 - Bitget
Creative Medical Technology Holdings, Inc. (CELZ) stock price, news, quote and history - Yahoo Finance Singapore
Creative Medical Technology Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. 2026: Revenue $0 Net income ($1.51M), EPS ($0.41) — 10-Q Summary - TradingView
Creative Medical Technology (NASDAQ: CELZ) Q2 loss, cash rises to $8.7M - Stock Titan
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Top Microcaps CELZ, PRSO, HCWC, TOON: Shorted Stocks to Watch in August 2026 - FinancialContent
Which stocks have an unusual volume on Friday? - ChartMill
Creative Medical Technology Holdings Inc (CELZ) Stock News Today - TradingKey
$Creative Medical Technology (CELZ.US)$ 小赚 - Moomoo
$Creative Medical Technology (CELZ.US)$ sky is so clear and the sun is out 🌄 - Moomoo
CELZ Stock Jumps As New Diabetes Patent Fuels Momentum - stockstotrade.com
Creative Medical Technology Holdings Inc (CELZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
$Creative Medical Technology (CELZ.US)$ 🫣 - Moomoo
$Creative Medical Technology (CELZ.US)$ double dipped😋 - Moomoo
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Creative Medical Technology Stock Surges After Key Patent Win - Benzinga
Thursday's session: most active stocks - ChartMill
Medical Stocks To ConsiderAugust 6th - MarketBeat
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Creative Medical receives patent allowance for diabetes exosome tech By Investing.com - Investing.com South Africa
Creative Medical Technology Holdings Shares Surge as Traders Appear to Latch Onto Earlier Pipeline Updates and a Tiny-float Setup - Moomoo
Creative Medical receives patent allowance for diabetes exosome tech - Investing.com
Creative Medical Receives U.S. Patent Allowance for Exosome-Based Type 1 Diabetes Immunotherapy - Yahoo Finance
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms - marketscreener.com
Exosome application gets U.S. allowance to target Type 1 diabetes autoimmunity - Stock Titan
CELZ Stock Slides As Traders Track High-Volatility Setup - StocksToTrade
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):